J
Jie Na
Researcher at Mayo Clinic
Publications - 23
Citations - 1725
Jie Na is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 9, co-authored 17 publications receiving 958 citations.
Papers
More filters
Journal ArticleDOI
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Fergus J. Couch,Hermela Shimelis,Chunling Hu,Steven N. Hart,Eric C. Polley,Jie Na,Emily Hallberg,Raymond Moore,Abigail Thomas,Jenna Lilyquist,Bing Jian Feng,Rachel McFarland,Tina Pesaran,Robert Huether,Holly LaDuca,Elizabeth C. Chao,David E. Goldgar,Jill S. Dolinsky +17 more
TL;DR: Several panel genes are established as high- and moderate-risk breast cancer genes and estimates of breast cancer risk associated with pathogenic variants in these genes among individuals qualifying for clinical genetic testing are provided.
Journal ArticleDOI
Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer.
Chunling Hu,Steven N. Hart,Eric C. Polley,Rohan Gnanaolivu,Hermela Shimelis,Kun Y. Lee,Jenna Lilyquist,Jie Na,Raymond Moore,Samuel O. Antwi,William R. Bamlet,Kari G. Chaffee,John DiCarlo,Zhong Wu,Raed Samara,Pashtoon Murtaza Kasi,Robert R. McWilliams,Gloria M. Petersen,Fergus J. Couch +18 more
TL;DR: To determine whether inherited germline mutations in cancer predisposition genes are associated with increased risks of pancreatic cancer, a case-control study of patients diagnosed as having pancreaticcancer and enrolled in a Mayo Clinic registry between October 12, 2000, and March 31, 2016 was conducted.
Journal ArticleDOI
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Chunling Hu,Steven N. Hart,Rohan Gnanaolivu,Hongyan Huang,Kun Y. Lee,Jie Na,Chi Gao,Jenna Lilyquist,Siddhartha Yadav,Nicholas J. Boddicker,Raed Samara,Josh Klebba,Christine B. Ambrosone,Hoda Anton-Culver,Paul L. Auer,Elisa V. Bandera,Leslie Bernstein,Kimberly A. Bertrand,Elizabeth S. Burnside,Brian D. Carter,Heather Eliassen,Susan M. Gapstur,Mia M. Gaudet,Christopher A. Haiman,James M. Hodge,David J. Hunter,David J. Hunter,Eric J. Jacobs,Esther M. John,Charles Kooperberg,Allison W. Kurian,Loic Le Marchand,Sara Lindstroem,Tricia Lindstrom,Huiyan Ma,Susan L. Neuhausen,Polly A. Newcomb,Katie M. O'Brien,Janet E. Olson,Irene M. Ong,Tuya Pal,Julie R. Palmer,Alpa V. Patel,Sonya Reid,Lynn Rosenberg,Dale P. Sandler,Christopher G. Scott,Rulla M. Tamimi,Jack A. Taylor,Amy Trentham-Dietz,Celine M. Vachon,Clarice R. Weinberg,Song Yao,Argyrios Ziogas,Jeffrey N. Weitzel,David E. Goldgar,Susan M. Domchek,Katherine L. Nathanson,Peter Kraft,Eric C. Polley,Fergus J. Couch +60 more
TL;DR: In this paper, population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and risk assessment.
Journal ArticleDOI
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Hermela Shimelis,Holly LaDuca,Chunling Hu,Steven N. Hart,Jie Na,Abigail Thomas,Margaret Akinhanmi,Raymond Moore,Hiltrud Brauch,Hiltrud Brauch,Hiltrud Brauch,Angela Cox,Diana Eccles,Amanda Ewart-Toland,Peter A. Fasching,Peter A. Fasching,Florentia Fostira,Judy Garber,Andrew K. Godwin,Irene Konstantopoulou,Heli Nevanlinna,Priyanka Sharma,Drakoulis Yannoukakos,Song Yao,Bing Jian Feng,Brigette Tippin Davis,Jenna Lilyquist,Tina Pesaran,David E. Goldgar,Eric C. Polley,Jill S. Dolinsky,Fergus J. Couch +31 more
TL;DR: Multigene hereditary cancer panel testing can identify women with elevated risk of TNBC due to mutations in BARD1, BRCA1,BRCA2, PALB2, and RAD51D, and these women can potentially benefit from improved screening, risk management, and cancer prevention strategies.
Journal ArticleDOI
A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients
Holly LaDuca,Eric C. Polley,Amal Yussuf,Lily Hoang,Stephanie Gutierrez,Steven N. Hart,Siddhartha Yadav,Chunling Hu,Jie Na,David E. Goldgar,Kelly Fulk,Laura Panos Smith,Carolyn Horton,Jessica Profato,Tina Pesaran,Chia Ling Gau,Melissa Pronold,Brigette Tippin Davis,Elizabeth C. Chao,Fergus J. Couch,Jill S. Dolinsky +20 more
TL;DR: Opportunities to improve upon identification of patients at risk for hereditary cancer predisposition include revising BRCA1/2 and Lynch syndrome testing criteria to include additional clinically actionable genes with overlapping phenotypes and relaxing testing criteria for associated cancers.